STOCK TITAN
  1. Home
  2. News
  3. NXLIW

Nexalin Tech (NXLIW) Stock News

NXLIW Nasdaq

Welcome to our dedicated page for Nexalin Tech news (Ticker: NXLIW), a resource for investors and traders seeking the latest updates and insights on Nexalin Tech stock.

Nexalin Technology, Inc. develops non-invasive Deep Intracranial Frequency Stimulation (DIFS™) technology for brain-health and mental-health indications. Company news centers on clinical evidence for its neurostimulation platform, including peer-reviewed studies involving insomnia, depression-related symptoms, traumatic brain injury, PTSD, Alzheimer’s disease, dementia-related cognitive decline and ADHD.

Updates also cover the HALO™ Clarity headset, the NeuroCare® virtual clinic platform, collaborations with clinical research and academic organizations, FDA De Novo strategy, international regulatory activity, and public-company events affecting Nexalin securities.

News

Nexalin Technology Announces Positive Results from Clinical Study of its Gen-2 tACS Device for Treating Adult Patients with Chronic Insomnia

Rhea-AI Summary

Summary not available.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.43%
Tags
clinical trial
-
News

Nexalin Technology Announces Regulatory Approval in Oman for Gen-2 Neurostimulation Device

Rhea-AI Summary

Summary not available.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1%
Tags
none
-
News

Nexalin Technology Awarded Key Patent Related to its Non-Invasive, Frequency-Based Deep-Brain Stimulation Device – the Transcranial Alternating Current Dynamic Frequency Stimulation (TACS) System

Rhea-AI Summary

Summary not available.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
21.95%
Tags
none
News

Nexalin Technology Unveils Next-Generation HALO™ Clarity

Rhea-AI Summary

Summary not available.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-14.77%
Tags
none
-
News

Nexalin Technology Reports Significant Positive Results of Clinical Study Supporting the Therapeutic Benefits of its Gen-2, 15 Milliamp Neurostimulation Device on Treatment-Resistant Depression

Rhea-AI Summary

Summary not available.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
clinical trial
-
News

Nexalin Technology Announces Formation of New Military & Government Advisory Board to be Led by Government Affairs Veteran David Lasseter

Rhea-AI Summary

Summary not available.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.64%
Tags
management
News

Nexalin Technology Reports Results of Clinical Study Supporting the Therapeutic Benefits of its Gen-2, 15 Milliamp Neurostimulation Device in Treating Migraine Headaches and Related Symptoms

Rhea-AI Summary

Summary not available.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-41.82%
Tags
clinical trial
-
News

Nexalin’s CEO Mark White to be Interviewed Live on “The Big Biz Show” Today at 3PM Eastern Time

Rhea-AI Summary

Summary not available.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
News

Nexalin Technology Announces New Public Sector Division to Capitalize on Opportunities to Serve U.S. Government Agencies

Rhea-AI Summary

Summary not available.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
News

Nexalin Technology Announces Abstract Accepted for Presentation at 2023 Military Health System Research Symposium Validating the Potential of its Non-Invasive, Frequency-Based Deep-Brain Stimulation Device for the Treatment of Mild Traumatic Brain Injury

Rhea-AI Summary

Summary not available.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.68%
Tags
none

FAQ

What is the current stock price of Nexalin Tech (NXLIW)?

The current stock price of Nexalin Tech (NXLIW) is $0.0138 as of September 19, 2025.